By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ipsen 

39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609


SEARCH JOBS


Industry
Pharmaceutical






Company News
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 1/26/2015 10:11:48 AM
Ipsen (IPN.PA) To Present Further Data On Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (Lanreotide), At Gastrointestinal Cancers Symposium 1/13/2015 7:33:08 AM
Ipsen (IPN.PA) Announces FDA Approval Of Somatuline® Depot® (Lanreotide) Injection For The Treatment Of Gastroenteropancreatic Neuroendocrine Tumors 12/17/2014 11:04:33 AM
François Garnier Appointed Executive Vice President, General Counsel Of Ipsen (IPN.PA) 12/16/2014 10:21:10 AM
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014 10:08:33 AM
Ipsen (IPN.PA) Announces FDA Acceptance Of Filing For Dysport® In The Treatment Of Upper Limb Spasticity In Adult Patients 12/1/2014 12:03:35 PM
Ipsen (IPN.PA) And CNRS Create The "Archi-Pex" Joint Research And Innovation Lab, In Collaboration With The University Of Rennes 1 And CEA 11/20/2014 1:41:55 PM
Ipsen (IPN.PA) And Salk Institute for Biological Studies Renew Their Agreement For Discovery Research In Medical Sciences 11/18/2014 12:57:36 PM
Ipsen (IPN.PA) Announces FDA Approval Of A New Delivery Device For Somatuline® Depot® (Lanreotide) Injection 11/6/2014 11:06:28 AM
Otonomy, Inc. (OTIC) Obtains Rights To Gacyclidine Data From Ipsen (IPN.PA) To Support Development Of OTO-311 As A Treatment For Tinnitus 11/6/2014 11:02:22 AM
12345678910...
//-->